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Addressing Cervical Cancer in Central Appalachia
Baretta R. Casey, MD, MPH1; Richard A. Crosby, PhD2;Wallace Bates1; Tonya D. Godsey1; and Mark B. Dignan, PhD, MPH3
Center for Excellence in Rural Health-Hazard1, College of Public Health2, and Department of Internal Medicine3, University of Kentucky
METHODS
Procedures: Gardasil was provided at no cost. To avoid self- 
selection bias in the sample, the project was called the Women’s 
Health Study and reference to free Gardasil was avoided entirely.
Compensation: After providing consent, women completed a self- 
administered questionnaire that assessed numerous 
psychosocial factors potentially related to Gardasil acceptance. 




Three items were assessed using “ever” as the recall period: 
ever having an abnormal Pap test result, an STD, or having a 
friend/family diagnosed with cervical cancer. 

 
One item asked, “How often do you worry that you might have 
HPV?” Response options were provided on a 4-point scale 
ranging from “never” to “frequently.”

 
Three items assessed normative influences. The first asked, 
“Do you think your friends would want you to be vaccinated 
against HPV?” Two subsequent items replaced the word “friends” 
with “mother” and then with “father.”

 
A series of statements were provided to women, with each 
statement reflecting a factor potentially associated with vaccine 
acceptance. Response options were provided on a 5-point scale 
ranging from (1) “strongly agree” to (5) “strongly disagree.”
Analysis: Because the study is on-going, many women receiving 
dose 1 have not yet been due for dose 2 or dose 3. Thus, this 
preliminary analysis only compared women receiving dose 1 to 
those declining dose 1. Associations between continuous 
correlates and HPV vaccine acceptance were assessed by 
independent group t-tests. Associations between dichotomous 
correlates and HPV vaccine acceptance were assessed by the use 
of contingency table analyses to calculate prevalence ratios, their 
95% confidence intervals, and their respective p values. 
Correlates achieving significance were entered into a multiple 
logistic regression model using forward stepwise entry. 
Multivariate significance was defined by an alpha level of .05 or 
less.
ABSTRACT
Rural women, particularly those residing in central Appalachia, 
have some of the nation’s highest cervical cancer mortality rates. 
With support from a federal (U.S. Centers for Disease Control and 
Prevention) and private (Merck) grant, the University of Kentucky 
Center for Excellence in Rural Health-Hazard is attempting to 
address this issue. Two Eastern Kentucky-based researchers 
have surveyed 350 18- to 26-year-old female community health 
center patients and college students about their risk factors for 
the disease. The young women are then offered free Gardasil, a 
vaccine against the virus that causes most cervical cancer cases. 
The purpose of this project is to determine the prevalence of 
Quadrivalent Human Papillomavirus Recombinant Vaccine 
acceptance among traditional university-age women and to 
identify non-cost, psychosocial factors associated with 
acceptance. 
CONCLUSIONS
1. Even when we offered Gardasil for free the uptake was poor. Social marketing programs are 
needed to promote increased uptake among young rural women (and someday soon, young rural 
men).
2. Findings also suggest that daughters’ perceptions of their fathers’ endorsement of HPV 
vaccination may be critical to acceptance – more so than mother’s or friends’ endorsement.
3. The experience of having an abnormal Pap test result may be a “window of opportunity” for 
providers to offer Gardasil.
4. Vaccine safety and ease of return for boosters are critical perceptions – each can potentially be 




Average age of the sample was 21.3 years (standard deviation = 2.5 years). The vast majority (98.6 
percent) self-identified as “Caucasian/white,” with the remainder identifying as members of other 




One hundred and two women received their first dose of Gardasil, leaving 248 (70.9 percent) who 
had not accepted the offer of free vaccination.

 
The mean age of women receiving the vaccine (21.5 years) was not significantly different than the 
mean age of those not accepting the vaccine (21.3 years) (t = .88; df = 348; p = .38).
Among participants who answered “yes” to having had an abnormal pap smear, 40.7 percent 
received dose 1 of Gardasil. For participants who answered “no,” only 25.1 percent accepted the free 
vaccine. (p = .005)
Figure 1 relates participants’ responses about whether friends or family members would “definitely 
want me to be vaccinated” to their subsequent decision about whether to accept a free dose of 
Gardasil. For instance, among participants answering “yes” with regard to their father, 38.7 percent 
received dose 1 of Gardasil; among those answering “no,” only 20.4 percent accepted the vaccine.
Table 1 presents statistically significant (p < .05) attitudinal differences between study participants 
who accepted dose 1 and those who did not. Answers to health belief questions were on a 5-point 
scale ranging from (1) “strongly agree” to (5) “strongly disagree.”
Table 2 shows factors that might have made a practical difference in participants’ decision about 
whether to accept the vaccine. However, none of these predictors were impactful to a statistically 
significant degree (p < .05).






































































I am not sure the vaccine is safe 3.47 2.96 p = .0001






















































































1.66 95% CI = 1.12 – 2.44 p = .01
12% greater odds of 
 
decline for each unit 
 
of more agreement 
 
with this statement
Less agreement 
 
with the 
 
statement that 
 
the vaccine is 
 
not safe
.65 95% CI = .59 ‐
 
.85 p
 
= .002
This is a protective 
 
effect meaning that 
 
for each unit of “less 
 
agreement”
 
on the 5‐
 
point scale young 
 
women were 35% less 
 
likely to decline the 
 
free offer of Gardasil
Source: University of Kentucky “Predictors of HPV Vaccine Acceptance Among Young 
 
Rural Women”
 
study data, 2009
